Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent
- Details
- Category: Bayer
Bayer HealthCare and Onyx Pharmaceuticals, Inc. today announced that Nexavar® (sorafenib) tablets significantly improved overall survival by 47.3 percent (HR=0.68; p-value=0.014) in patients in the Asia-Pacific region with advanced hepatocellular carcinoma (HCC), or primary liver cancer, versus those receiving placebo.
Pfiser's List of Grants and Charitable Contributions
- Details
- Category: Pfizer
Pfizer announced that it has posted a list of U.S. medical, scientific and patient organization grants and charitable contributions made in the first quarter of this year, part of an ongoing drive throughout the company to increase transparency.
Lapatinib (Tykerb/Tyverb) to be investigated in landmark early breast cancer trial
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK), in collaboration with the Breast International Group (BIG), a leading academic breast cancer research network, and one of its member groups, the Spanish Breast Cancer Cooperative Group (SOLTI), announced the start of a global Phase III study that will examine the role of lapatinib (Tykerb®/Tyverb®)in the treatment of early breast cancer (EBC).
Boehringer Ingelheim announces commitment to progressing science with the Bouquet Studies
- Details
- Category: Boehringer Ingelheim
Data announced at the American College of Obstetricians and Gynaecologists (ACOG) annual clinical meeting suggest that up to one in ten women are suffering from a condition called hypoactive sexual desire disorder (HSDD) with only a third of these seeking advice or help from their healthcare professional.[1]
Actemra inhibits joint damage and improves physical function of patients with Rheumatoid Arthritis
- Details
- Category: Roche
Roche announced that Actemra (tocilizumab) can significantly inhibit structura[1] damage to joints in patients with rheumatoid arthritis (RA), a critical measure of effectiveness of an RA treatment. Actemra also improved the patients' physical function after one year of therapy, leading to a better quality of life.
International study to evaluate efficacy and safety in treating a leading cause of blindness
- Details
- Category: Bayer
Bayer HealthCare AG and development partner Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD), a leading cause of blindness in adults.
Highlight Potential of Novel Oral Compound for Gaucher Disease
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ) reported that a preliminary analysis of data from an ongoing open-label Phase 2 clinical trial of its investigational oral therapy Genz-112638 showed that the compound produced a meaningful impact on key clinical manifestations of Gaucher disease.
More Pharma News ...
- Bayer Schering Pharma to market new low-dose oral contraceptive YAZ® in Europe
- European Commission grants full approval of HIV protease inhibitor, tipranavir (Aptivus®)
- Novo Nordisk researchers nominated for Europe's top innovation prize
- GlaxoSmithKline commences tender offer to acquire Sirtris Pharmaceuticals
- Abbott, Takeda Conclude TAP Joint Venture
- Esperion Therapeutics Completes $22.75 M Series A Financing
- Lundbeck expands geographical rights for Circadin®